Holen Sie sich die Stockscreener-App
1.65
3.51%
-0.06
Handel nachbörslich:
1.73
0.08
+4.85%
Schlusskurs vom Vortag:
$1.71
Offen:
$1.74
24-Stunden-Volumen:
120.09K
Relative Volume:
1.07
Marktkapitalisierung:
$95.30M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.38M
KGV:
-4.2308
EPS:
-0.39
Netto-Cashflow:
$-25.19M
1W Leistung:
+3.12%
1M Leistung:
+10.74%
6M Leistung:
+99.98%
1J Leistung:
+39.83%
1-Tages-Spanne:
$1.57
$1.74
1-Wochen-Bereich:
$1.46
$1.74
52-Wochen-Spanne:
$0.51
$2.86
Connect Biopharma Holdings Ltd Stock (CNTB) Company Profile
Firmenname
Connect Biopharma Holdings Ltd
Sektor
Branche
Telefon
858-727-1040
Adresse
3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO
Vergleichen Sie CNTB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNTB
Connect Biopharma Holdings Ltd
|
1.65 | 95.30M | 0 | -21.38M | -25.19M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Connect Biopharma Holdings Ltd Stock (CNTB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Eingeleitet | BTIG Research | Buy |
| 2025-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-13 | Eingeleitet | Jefferies | Buy |
| 2021-04-13 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-13 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Connect Biopharma Holdings Ltd Aktie (CNTB) Neueste Nachrichten
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3 - Bucyrus Telegraph-Forum
This Immuneering Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Connect Biopharma stock initiated with Buy rating at BTIG on respiratory drug potential - Investing.com Nigeria
BTIG Initiates Coverage on Connect Biopharma Hldgs (CNTB) with 'Buy' Rating | CNTB Stock News - GuruFocus
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Short Interest Update - MarketBeat
Connect Biopharma (NASDAQ:CNTB) Stock Price Down 3.8%What's Next? - MarketBeat
All In Solutions Detox Enhances California Center Recovery Environment Through Tranquil Setting - The News Journal
RestoPros of Southwest Florida Expands Damage Restoration Services Across Multiple Counties - azcentral.com and The Arizona Republic
Connect Biopharma's (CNTB) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Hyperke Growth Partners Reveals How They Help SEO Agencies with Qualified Lead Generation in Case Study - azcentral.com and The Arizona Republic
Connect Biopharma's (CNTB) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Severe Asthma Pipeline 2025: Therapies Under Investigation, - openPR.com
Connect Biopharma (NASDAQ:CNTB) Stock Price Up 7.4%Still a Buy? - MarketBeat
Connect Biopharma Holdings Limited (CNTB) stock price, news, quote and history - Yahoo
October 2025's Promising Penny Stocks To Consider - Yahoo Finance
Short Interest in Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Drops By 53.6% - MarketBeat
H.C. Wainwright reiterates Buy rating on Connect Biopharma stock at $7 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on Connect Biopharma stock at $7 target - Investing.com Nigeria
507mL Lung Function Improvement: Connect Bio's New Asthma Drug Shows Remarkable Results in High-Risk Patients - Stock Titan
James Huang to join CASI Pharmaceuticals board as independent director By Investing.com - Investing.com Australia
CASI Pharmaceuticals Appoints James Huang to Board of Directors - ACCESS Newswire
35-Year Biotech Veteran James Huang Joins CASI Pharma Board as Company Advances CID-103 Program - Stock Titan
Eosinophilic Asthma Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharma - Barchart.com
Eosinophilic Asthma Pipeline 2025: Therapies, MOA Insights, - openPR.com
FY2025 EPS Estimate for Connect Biopharma Lowered by Analyst - MarketBeat
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Sees Large Drop in Short Interest - MarketBeat
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Short Interest Up 204.8% in August - MarketBeat
Asthma Market to Show Paltry Growth at a CAGR of 1.95% During the Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Sees Large Increase in Short Interest - Defense World
Connect Biopharma Announces Poster Presentations of Rademikibart at the European Respiratory Society Congress 2025 - Quiver Quantitative
New Asthma Treatment Data: Connect Biopharma's Rademikibart Shows Impact on FEV1 in Type 2 Asthma Trial - Stock Titan
Connect Biopharma completes termination of its American depositary receipt program and directly lists its ordinary shares on Nasdaq - MarketScreener
Connect Biopharma Ends ADR Program, Moves to Direct Nasdaq Listing; Shares Up Premarket - MarketScreener
Connect Biopharma Completes Termination of its American - GlobeNewswire
Biotech Connect Biopharma Completes Strategic Shift to Direct Nasdaq Listing for U.S. Growth - Stock Titan
COPD Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Sanofi, MedImmune, EpiEndo Pharma, Tetherex Pharma - Barchart.com
3 Penny Stocks To Watch With Market Caps Over $100M - simplywall.st
Connect Biopharma (CNTB) Expected to Announce Quarterly Earnings on Friday - Defense World
Connect Biopharma Holdings Limited to Participate in Upcoming Healthcare Conferences - Quiver Quantitative
Clinical-Stage Biotech Connect Biopharma Announces Key September Investor Conference Appearances - Stock Titan
Finanzdaten der Connect Biopharma Holdings Ltd-Aktie (CNTB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):